# Axcelis Technologies Inc: financial statements, quarterly

ACLS · Nasdaq · CIK 1113232 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/acls.md) · [Financials](/companies/acls/financials.md) · [Filings](/companies/acls/filings.md) · [Insiders](/companies/acls/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/acls/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [292](/filings/0001558370-24-014856.md) | [310 d](/filings/0001104659-26-020461.md) | [252](/filings/0001558370-25-006534.md) | [257](/filings/0001558370-25-010325.md) | [257](/filings/0001104659-25-107689.md) | [252 d](/filings/0001104659-26-020461.md) | [193](/filings/0001104659-26-057725.md) | [195](/filings/0001104659-26-091999.md) | [214](/filings/0001104659-25-107689.md) | [238 d](/filings/0001104659-26-020461.md) | [199](/filings/0001104659-26-057725.md) | [215](/filings/0001104659-26-091999.md) |
| Cost of revenue | $m | [163](/filings/0001558370-24-014856.md) | [172 d](/filings/0001104659-26-020461.md) | [136](/filings/0001558370-25-006534.md) | [144](/filings/0001558370-25-010325.md) | [147](/filings/0001104659-25-107689.md) | [136 d](/filings/0001104659-26-020461.md) | [104](/filings/0001104659-26-057725.md) | [107](/filings/0001104659-26-091999.md) | [125](/filings/0001104659-25-107689.md) | [126 d](/filings/0001104659-26-020461.md) | [118](/filings/0001104659-26-057725.md) | [124](/filings/0001104659-26-091999.md) |
| Gross profit | $m | [130](/filings/0001558370-24-014856.md) | [138 d](/filings/0001104659-26-020461.md) | [116](/filings/0001558370-25-006534.md) | [112](/filings/0001558370-25-010325.md) | [110](/filings/0001104659-25-107689.md) | [116 d](/filings/0001104659-26-020461.md) | [88.8](/filings/0001104659-26-057725.md) | [87.3](/filings/0001104659-26-091999.md) | [88.8](/filings/0001104659-25-107689.md) | [112 d](/filings/0001104659-26-020461.md) | [80.6](/filings/0001104659-26-057725.md) | [91.2](/filings/0001104659-26-091999.md) |
| Research and development | $m | [24.1](/filings/0001558370-24-014856.md) | [24.9 d](/filings/0001104659-26-020461.md) | [25.7](/filings/0001558370-25-006534.md) | [25.8](/filings/0001558370-25-010325.md) | [26.4](/filings/0001104659-25-107689.md) | [27.7 d](/filings/0001104659-26-020461.md) | [27.1](/filings/0001104659-26-057725.md) | [27.1](/filings/0001104659-26-091999.md) | [24.6](/filings/0001104659-25-107689.md) | [30.1 d](/filings/0001104659-26-020461.md) | [28.5](/filings/0001104659-26-057725.md) | [29.0](/filings/0001104659-26-091999.md) |
| Operating income | $m | [71.7](/filings/0001558370-24-014856.md) | [79.1 d](/filings/0001104659-26-020461.md) | [56.5](/filings/0001558370-25-006534.md) | [52.8](/filings/0001558370-25-010325.md) | [46.9](/filings/0001104659-25-107689.md) | [54.5 d](/filings/0001104659-26-020461.md) | [29.2](/filings/0001104659-26-057725.md) | [29.0](/filings/0001104659-26-091999.md) | [25.0](/filings/0001104659-25-107689.md) | [36.2 d](/filings/0001104659-26-020461.md) | [8.0](/filings/0001104659-26-057725.md) | [20.3](/filings/0001104659-26-091999.md) |
| Interest expense | $m | [1.3](/filings/0001558370-23-017452.md) | [1.3 d](/filings/0001558370-24-001969.md) | [1.3](/filings/0001558370-24-006510.md) | [1.3](/filings/0001558370-25-010325.md) | [1.3](/filings/0001104659-25-107689.md) | [1.4 d](/filings/0001104659-26-020461.md) | [1.4](/filings/0001104659-26-057725.md) | [1.4](/filings/0001104659-26-091999.md) | [1.3](/filings/0001104659-25-107689.md) | [1.3 d](/filings/0001104659-26-020461.md) | [1.3](/filings/0001104659-26-057725.md) | [1.3](/filings/0001104659-26-091999.md) |
| Income tax | $m | [7.7](/filings/0001558370-24-014856.md) | [16.4 d](/filings/0001104659-26-020461.md) | [7.4](/filings/0001558370-25-006534.md) | [6.4](/filings/0001558370-25-010325.md) | [6.8](/filings/0001104659-25-107689.md) | [8.7 d](/filings/0001104659-26-020461.md) | [4.5](/filings/0001104659-26-057725.md) | [3.6](/filings/0001104659-26-091999.md) | [4.2](/filings/0001104659-25-107689.md) | [5.7 d](/filings/0001104659-26-020461.md) | [1.4](/filings/0001104659-26-057725.md) | [2.1](/filings/0001104659-26-091999.md) |
| Net income | $m | [65.9](/filings/0001558370-24-014856.md) | [71.1 d](/filings/0001104659-26-020461.md) | [51.6](/filings/0001104659-25-107689.md) | [50.9](/filings/0001104659-25-107689.md) | [48.6](/filings/0001104659-25-107689.md) | [50.0 d](/filings/0001104659-26-020461.md) | [28.6](/filings/0001104659-26-091999.md) | [31.4](/filings/0001104659-26-091999.md) | [26.0](/filings/0001104659-25-107689.md) | [34.3 d](/filings/0001104659-26-020461.md) | [9.2](/filings/0001104659-26-091999.md) | [23.3](/filings/0001104659-26-091999.md) |
| Diluted EPS | $ per share | [1.99](/filings/0001558370-24-014856.md) | not reported | [1.57](/filings/0001558370-25-006534.md) | [1.55](/filings/0001558370-25-010325.md) | [1.49](/filings/0001104659-25-107689.md) | not reported | [0.88](/filings/0001104659-26-057725.md) | [0.98](/filings/0001104659-26-091999.md) | [0.83](/filings/0001104659-25-107689.md) | not reported | [0.30](/filings/0001104659-26-057725.md) | [0.75](/filings/0001104659-26-091999.md) |
| Basic EPS | $ per share | [2.01](/filings/0001558370-24-014856.md) | not reported | [1.58](/filings/0001558370-25-006534.md) | [1.56](/filings/0001558370-25-010325.md) | [1.49](/filings/0001104659-25-107689.md) | not reported | [0.89](/filings/0001104659-26-057725.md) | [0.99](/filings/0001104659-26-091999.md) | [0.83](/filings/0001104659-25-107689.md) | not reported | [0.30](/filings/0001104659-26-057725.md) | [0.76](/filings/0001104659-26-091999.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [142](/filings/0001558370-23-017452.md) | [167](/filings/0001558370-25-001855.md) | [134](/filings/0001558370-24-006510.md) | [145](/filings/0001558370-24-010589.md) | [120](/filings/0001558370-24-014856.md) | [124](/filings/0001104659-26-020461.md) | [184](/filings/0001558370-25-006534.md) | [174](/filings/0001558370-25-010325.md) | [188](/filings/0001104659-25-107689.md) | [145](/filings/0001104659-26-091999.md) | [151](/filings/0001104659-26-057725.md) | [155](/filings/0001104659-26-091999.md) |
| Current assets | $m | [1,015](/filings/0001558370-23-017452.md) | [1,080](/filings/0001558370-25-001855.md) | [1,105](/filings/0001558370-24-006510.md) | [1,078](/filings/0001558370-24-010589.md) | [1,122](/filings/0001558370-24-014856.md) | [1,124](/filings/0001104659-26-020461.md) | [1,114](/filings/0001558370-25-006534.md) | [1,064](/filings/0001558370-25-010325.md) | [984](/filings/0001104659-25-107689.md) | [943](/filings/0001104659-26-091999.md) | [936](/filings/0001104659-26-057725.md) | [980](/filings/0001104659-26-091999.md) |
| Total assets | $m | [1,202](/filings/0001558370-23-017452.md) | [1,282](/filings/0001558370-25-001855.md) | [1,307](/filings/0001558370-24-006510.md) | [1,288](/filings/0001558370-24-010589.md) | [1,338](/filings/0001558370-24-014856.md) | [1,349](/filings/0001104659-26-020461.md) | [1,341](/filings/0001558370-25-006534.md) | [1,323](/filings/0001558370-25-010325.md) | [1,352](/filings/0001104659-25-107689.md) | [1,361](/filings/0001104659-26-091999.md) | [1,375](/filings/0001104659-26-057725.md) | [1,387](/filings/0001104659-26-091999.md) |
| Current liabilities | $m | [261](/filings/0001558370-23-017452.md) | [285](/filings/0001558370-25-001855.md) | [277](/filings/0001558370-24-006510.md) | [244](/filings/0001558370-24-010589.md) | [252](/filings/0001558370-24-014856.md) | [208](/filings/0001104659-26-020461.md) | [200](/filings/0001558370-25-006534.md) | [177](/filings/0001558370-25-010325.md) | [199](/filings/0001104659-25-107689.md) | [198](/filings/0001104659-26-091999.md) | [204](/filings/0001104659-26-057725.md) | [200](/filings/0001104659-26-091999.md) |
| Total liabilities | $m | [401](/filings/0001558370-23-017452.md) | [417](/filings/0001558370-25-001855.md) | [405](/filings/0001558370-24-006510.md) | [353](/filings/0001558370-24-010589.md) | [363](/filings/0001558370-24-014856.md) | [336](/filings/0001104659-26-020461.md) | [313](/filings/0001558370-25-006534.md) | [301](/filings/0001558370-25-010325.md) | [332](/filings/0001104659-25-107689.md) | [327](/filings/0001104659-26-091999.md) | [330](/filings/0001104659-26-057725.md) | [321](/filings/0001104659-26-091999.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [801](/filings/0001558370-24-014856.md) | [865](/filings/0001104659-26-020461.md) | [902](/filings/0001104659-25-107689.md) | [935](/filings/0001104659-25-107689.md) | [976](/filings/0001104659-25-107689.md) | [1,013](/filings/0001104659-26-091999.md) | [1,027](/filings/0001104659-26-091999.md) | [1,022](/filings/0001104659-26-091999.md) | [1,020](/filings/0001104659-25-107689.md) | [1,035](/filings/0001104659-26-091999.md) | [1,045](/filings/0001104659-26-091999.md) | [1,066](/filings/0001104659-26-091999.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [24.0 d](/filings/0001558370-24-014856.md) | [65.6 d](/filings/0001104659-26-020461.md) | [42.2](/filings/0001558370-25-006534.md) | [40.1 d](/filings/0001558370-25-010325.md) | [45.7 d](/filings/0001104659-25-107689.md) | [12.8 d](/filings/0001104659-26-020461.md) | [39.8](/filings/0001104659-26-057725.md) | [39.7 d](/filings/0001104659-26-091999.md) | [45.4 d](/filings/0001104659-25-107689.md) | [(6.6) d](/filings/0001104659-26-020461.md) | [18.1](/filings/0001104659-26-057725.md) | [18.4 d](/filings/0001104659-26-091999.md) |
| Capital expenditure | $m | [5.3 d](/filings/0001558370-24-014856.md) | [10.2 d](/filings/0001104659-26-020461.md) | [1.6](/filings/0001558370-25-006534.md) | [2.0 d](/filings/0001558370-25-010325.md) | [3.9 d](/filings/0001104659-25-107689.md) | [4.7 d](/filings/0001104659-26-020461.md) | [5.0](/filings/0001104659-26-057725.md) | [2.0 d](/filings/0001104659-26-091999.md) | [2.0 d](/filings/0001104659-25-107689.md) | [2.3 d](/filings/0001104659-26-020461.md) | [1.8](/filings/0001104659-26-057725.md) | [3.6 d](/filings/0001104659-26-091999.md) |
| Share repurchases | $m | [12.5 d](/filings/0001558370-24-014856.md) | [15.0 d](/filings/0001104659-26-020461.md) | [15.0](/filings/0001558370-25-006534.md) | [15.0 d](/filings/0001558370-25-010325.md) | [15.4 d](/filings/0001104659-25-107689.md) | [15.1 d](/filings/0001104659-26-020461.md) | [18.2](/filings/0001104659-26-057725.md) | [45.3 d](/filings/0001104659-26-091999.md) | [32.3 d](/filings/0001104659-25-107689.md) | [25.2 d](/filings/0001104659-26-020461.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.4](/filings/0001558370-23-017452.md) | [33.3](/filings/0001558370-24-006510.md) | [33.2](/filings/0001558370-24-010589.md) | [33.2](/filings/0001558370-24-014856.md) | [32.9](/filings/0001558370-25-006534.md) | [32.8](/filings/0001558370-25-010325.md) | [32.7](/filings/0001104659-25-107689.md) | [32.3](/filings/0001104659-26-057725.md) | [31.9](/filings/0001104659-26-091999.md) | [31.5](/filings/0001104659-25-107689.md) | [31.0](/filings/0001104659-26-057725.md) | [31.1](/filings/0001104659-26-091999.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,881,489 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-091999.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.